To date, the WHO has focused on handling the global tuberculosis problem by vaccinating infants with the attenuated M. bovis Bacillus Calmette-Guérin (BCG) vaccine and subsequently treating patients who test positive by sputum smear-microscopy, tuberculin skin test (TST), interferon-gamma release assay (IGRA), or tests with anti-mycobacterial therapy, followed by tracing and testing of potential contacts. The gene discussed is IFNG; the disease is tuberculosis.